Overview
Clinical phenotype terms— hover any for plain English:
FDA & Trial Timeline
10 eventsVA Office of Research and Development — PHASE3
University of Stirling — NA
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences — PHASE2
Sanofi — PHASE4
Incyte Corporation — PHASE2
Universitas Katolik Widya Mandala Surabaya — NA
Selcuk University
Hôpital Fribourgeois — NA
M.D. Anderson Cancer Center
Apellis Pharmaceuticals, Inc. — PHASE3
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
4 availableIMBRUVICA
IMBRUVICA is indicated for the treatment of adult and pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.
Rezurock
REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic t…
REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
JAKAFI
treatment of chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older
Niktimvo
treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg
Rare Disease Specialist
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
3 resourcesOrencia
Bristol-Myers Squibb Co.
Orencia Patient Support (BMS Access Support)
Travel Grants
No travel grants are currently matched to Chronic graft versus host disease.
Community
No community posts yet. Be the first to share your experience with Chronic graft versus host disease.
Start the conversation →Latest news about Chronic graft versus host disease
5 articlesCaregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Chronic graft versus host disease
Are there clinical trials for Chronic graft versus host disease?
Yes — 20 recruiting clinical trials are currently listed for Chronic graft versus host disease on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Chronic graft versus host disease?
25 specialists and care centers treating Chronic graft versus host disease are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Chronic graft versus host disease?
2 patient support programs are currently tracked on UniteRare for Chronic graft versus host disease. See the treatments and support programs sections for copay assistance, eligibility, and contact details.